Corcept Therapeutics CORT
NASDAQ CORT
$75.03 +2.26 (+3.11%)
At close: Nov 9, 2026 · 4:00 PM EST

Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2010 - 2026)

Updated

Corcept Therapeutics (CORT) posted Net Income towards Common Stockholders of $124.49 million for Q3 2026, up 543.1% from $19.36 million a year earlier and up 195.4% from the prior quarter.

Analysis

Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

For the trailing twelve months through Sep 30, 2026, Net Income towards Common Stockholders at Corcept Therapeutics was $159.33 million, up 52.3% year-over-year; for FY2025, it came in at $98.17 million, down 29.7% from FY2024.

  • Annual Net Income towards Common Stockholders shows a five-year compound annual growth rate of -1.5% (FY2020 to FY2025).
  • In prior years, Corcept Therapeutics' Net Income towards Common Stockholders was $139.73 million in FY2024 (+32.5%), $105.5 million in FY2023 (+4.2%), $101.29 million in FY2022 (-10.0%) and $112.51 million in FY2021 (+6.1%).
  • The Q3 2026 figure stands as the highest quarterly Net Income towards Common Stockholders in data going back to Q2 2010.
  • On a year-over-year basis, Net Income towards Common Stockholders increased in two of the last seven quarters, with growth averaging 65.0%.
  • The strongest year-over-year quarter for Net Income towards Common Stockholders in the past five years was Q3 2026, with growth of 543.1%; the weakest was Q3 2025, with a decline of 58.5%.
  • According to Business Quant data, Net Income towards Common Stockholders for the three prior quarters was $42.14 million (Q2 2026), -$31.2 million (Q1 2026) and $23.9 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn 210.00 Mn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn 4.22 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn - -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn 3.12 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn 2.43 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn 3.24 Bn
10 Corcept Therapeutics 7.99 Bn 6.60 Bn 335.86 Mn 124.49 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 124.49 Mn
Jun 30, 2026 42.14 Mn
Mar 31, 2026 -31.20 Mn
Dec 31, 2025 23.90 Mn
Sep 30, 2025 19.36 Mn
Jun 30, 2025 34.61 Mn
Mar 31, 2025 20.29 Mn
Dec 31, 2024 30.39 Mn
Sep 30, 2024 46.69 Mn
Jun 30, 2024 35.12 Mn
Mar 31, 2024 27.51 Mn
Dec 31, 2023 31.14 Mn
Sep 30, 2023 31.17 Mn
Jun 30, 2023 27.36 Mn
Mar 31, 2023 15.81 Mn
Dec 31, 2022 16.53 Mn
Sep 30, 2022 34.55 Mn
Jun 30, 2022 27.40 Mn
Mar 31, 2022 22.80 Mn
Dec 31, 2021 32.05 Mn
API Access

Corcept Therapeutics Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CORT&period=max&api_key=YOUR_API_KEY